ATAGI says Novavax vaccine for primary shots, not boosters
The first protein-based COVID-19 vaccine approved in Australia is expected to roll out from late February
ATAGI has recommended the Novavax vaccine be used for a primary course of COVID-19 inoculation — including as part of a mixed schedule — but not as a booster.
The spike protein-based adjuvanted vaccine, branded Nuvaxovid, was provisionally approved by the TGA last week.
The first batches of the vaccine, the fourth to be approved for Australia, were expected to be available in the week beginning 21 February, federal Health Minister Greg Hunt said on Monday.
GPs who are part of the rollout should have already received an expression-of-interest form, with the AMA tweeting Tuesday that the government advises it closes on Australia Day.
